


CLAIMS

1. A tartrate salt of a compound of formula I:



Formula I

2. A tartrate salt according to claim 1 wherein the tartrate is L-tartrate.
3. A crystalline form of the tartrate salt of claim 1 or claim 2.
4. The crystalline form of claim 3 having a characteristic powder diffraction pattern (XRPD) using a copper with major peaks at 2 theta values at about 9.1, 15.5, 17.0, 18.5, 21.8, 22.1, and 25.3.
5. The crystalline form of claim 3 or claim 4 having a solubility in water of between 0.8 mg/ml and 1.0 mg/ml.
6. The crystalline form of claim ~~5~~ 3 or claim ~~4~~ having a solubility in water of 0.9 mg/ml.
7. The crystalline form of any one of claims 3 to 5 having a melt onset of approximately between 172°Celsius to 174°Celsius.
8. The crystalline form of claim 7 having a melt onset of approximately 173°Celsius.
9. The crystalline form of any one of claims 3 to 8 having crystallinity of 80% or greater.
10. ~~A method of treating a proliferative disease using~~Use of the tartrate salt according to any one of claims 1 to 9 in the manufacture of a medicament for treating a proliferative disease.
11. The tartrate salt according to any one of claims 1 to 9 for use in treating a proliferative disease.
12. A pharmaceutical composition comprising a tartrate salt according to any one of claims 1 to 9.

13. The pharmaceutical composition of claim 12 wherein said composition is suitable for oral administration.